{"id":7897,"date":"2022-10-27T14:19:21","date_gmt":"2022-10-27T14:19:21","guid":{"rendered":"http:\/\/www.kerentech.com\/?p=7897"},"modified":"2024-02-23T10:10:23","modified_gmt":"2024-02-23T10:10:23","slug":"cell-and-life-therapeutics-announces-that-prof-ankur-jain-in-mit-biology-dept-joins-the-company-as-cso-and-the-opening-of-its-us-company","status":"publish","type":"post","link":"http:\/\/www.kerentech.com\/index.php\/2022\/10\/27\/cell-and-life-therapeutics-announces-that-prof-ankur-jain-in-mit-biology-dept-joins-the-company-as-cso-and-the-opening-of-its-us-company\/","title":{"rendered":"Cell and Life Therapeutics announces that Prof.Ankur Jain in MIT Biology Dept., joins the Company as CSO and   the opening of its US company."},"content":{"rendered":"\n<p>Cell and Life Therapeutics is developing next-generation small-molecule medicines to target the RNA cycle for treating neurodegenerative and oncology disorders.<\/p>\n\n\n\n<p>In collaboration with Jubilant Biosys, Cell and Life Therapeutic has established \u201cSTAR (<strong><u>S<\/u><\/strong>mall-molecule&nbsp;<strong><u>TA<\/u><\/strong>rgeting&nbsp;<strong><u>R<\/u><\/strong>NA biology)\u201d library platform.<\/p>\n\n\n\n<p>Recently Cell and Life Therapeutic has selected a preclinical candidate for muscle atrophy diseases and potentially immune-oncology modulators.<\/p>\n\n\n\n<p>Cell and Life Therapeutics also plans to establish a US corporation in Boston.<\/p>\n\n\n\n<p>Prof. Ankur Jain in MIT Biology Dept, its longtime collaborator and SAB member, has decided to join the company as CSO to advance its RNA Phase Separation (Condensate biology) pipeline.<\/p>\n\n\n\n<p>Cell and Life Therapeutic aims to revolutionize disease treatment by RNA-biology-modulating small molecule medicines.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"http:\/\/www.kerentech.com\/wp-content\/uploads\/2022\/10\/image.png\" alt=\"\" class=\"wp-image-7901\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Cell and Life Therapeutics is developing next-generation small-molecule medicines to target the RNA cycle for treating neurodegenerative and oncology disorders. In collaboration with Jubilant Biosys, Cell and Life Therapeutic has established \u201cSTAR (Small-molecule&nbsp;TArgeting&nbsp;RNA biology)\u201d library platform. Recently Cell and Life Therapeutic has selected a preclinical candidate for muscle atrophy diseases and potentially immune-oncology modulators. Cell [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7899,"comment_status":"closed","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[15],"tags":[],"_links":{"self":[{"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/posts\/7897"}],"collection":[{"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/comments?post=7897"}],"version-history":[{"count":1,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/posts\/7897\/revisions"}],"predecessor-version":[{"id":7900,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/posts\/7897\/revisions\/7900"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/media\/7899"}],"wp:attachment":[{"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/media?parent=7897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/categories?post=7897"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.kerentech.com\/index.php\/wp-json\/wp\/v2\/tags?post=7897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}